LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

LLY

1,132.64

+3.8%↑

JNJ

227.98

+1.77%↑

ABBV

223.43

+2.02%↑

UNH

396.26

+3.41%↑

MRK

119.26

+3.41%↑

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Open

SectorGezondheidszorg

8.66 -0.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.6

Max

9.04

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+224.6% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-42M 802M
Vorige openingsprijs	8.89
Vorige sluitingsprijs	8.66

Nieuwssentiment

By Acuity

50%

154 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 jun 2026, 23:22 UTC

Winsten

Belangrijke Marktbewegers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 jun 2026, 23:09 UTC

Populaire aandelen

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 jun 2026, 20:51 UTC

Winsten

Costco Reports 15% Sales Growth in May

3 jun 2026, 20:43 UTC

Winsten

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 jun 2026, 23:48 UTC

Marktinformatie

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 jun 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 jun 2026, 23:35 UTC

Marktinformatie

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 jun 2026, 23:15 UTC

Marktinformatie

Winsten

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 jun 2026, 22:08 UTC

Populaire aandelen

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 jun 2026, 21:54 UTC

Marktinformatie

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 jun 2026, 21:18 UTC

Winsten

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 jun 2026, 21:15 UTC

Winsten

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 jun 2026, 21:13 UTC

Winsten

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 jun 2026, 21:13 UTC

Winsten

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 jun 2026, 21:12 UTC

Winsten

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 jun 2026, 21:09 UTC

Winsten

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 jun 2026, 21:03 UTC

Winsten

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 jun 2026, 20:43 UTC

Winsten

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 jun 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 jun 2026, 20:37 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 jun 2026, 20:35 UTC

Winsten

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 jun 2026, 20:17 UTC

Winsten

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 jun 2026, 20:17 UTC

Winsten

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q Adj EPS $2.44 >AVGO

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q EPS $1.91 >AVGO

3 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q Rev $22.19B >AVGO

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

224.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 224.6%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

154 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.